Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases
Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peru...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Instituto Nacional de Salud
2018-04-01
|
| Series: | Revista Peruana de Medicina Experimental y Salud Pública |
| Subjects: | |
| Online Access: | https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/3599 |
| _version_ | 1819162836215005184 |
|---|---|
| author | Cindy Alcarraz Johana Muñiz Luis Mas Mivael Olivera Zaida Morante Manuel Alvarez Raul Mantilla Jhajaira Araujo Joseph Pinto |
| author_facet | Cindy Alcarraz Johana Muñiz Luis Mas Mivael Olivera Zaida Morante Manuel Alvarez Raul Mantilla Jhajaira Araujo Joseph Pinto |
| author_sort | Cindy Alcarraz |
| collection | DOAJ |
| description | Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with postsurgery levels of carcinoembryonic antigen 125 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival. |
| first_indexed | 2024-12-22T17:34:34Z |
| format | Article |
| id | doaj.art-3fbbfc4fce5141b986a2b2e51b2b499e |
| institution | Directory Open Access Journal |
| issn | 1726-4634 1726-4642 |
| language | Spanish |
| last_indexed | 2024-12-22T17:34:34Z |
| publishDate | 2018-04-01 |
| publisher | Instituto Nacional de Salud |
| record_format | Article |
| series | Revista Peruana de Medicina Experimental y Salud Pública |
| spelling | doaj.art-3fbbfc4fce5141b986a2b2e51b2b499e2022-12-21T18:18:32ZspaInstituto Nacional de SaludRevista Peruana de Medicina Experimental y Salud Pública1726-46341726-46422018-04-01351465410.17843/rpmesp.2018.351.35992007Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseasesCindy Alcarraz0Johana Muñiz1Luis Mas2Mivael Olivera3Zaida Morante4Manuel Alvarez5Raul Mantilla6Jhajaira Araujo7Joseph Pinto8Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogoInstituto Nacional de Enfermedades Neoplásicas. Lima, Perú. médico residente de oncologíaInstituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogoInstituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogoInstituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogoInstituto Nacional de Enfermedades Neoplásicas. Lima, Perú. médico cirujano ginecólogo oncólogoInstituto Nacional de Enfermedades Neoplásicas. Lima, Perú. estadísticoOncosalud, AUNA. Lima, Perú. biólogoOncosalud, AUNA. Lima, Perú. biólogoObjectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with postsurgery levels of carcinoembryonic antigen 125 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival.https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/3599neoplasias ováricasquimioterapiaterapia neoadyuvanteprocedimientos quirúrgicos de citorreducciónperú |
| spellingShingle | Cindy Alcarraz Johana Muñiz Luis Mas Mivael Olivera Zaida Morante Manuel Alvarez Raul Mantilla Jhajaira Araujo Joseph Pinto Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases Revista Peruana de Medicina Experimental y Salud Pública neoplasias ováricas quimioterapia terapia neoadyuvante procedimientos quirúrgicos de citorreducción perú |
| title | Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases |
| title_full | Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases |
| title_fullStr | Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases |
| title_full_unstemmed | Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases |
| title_short | Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases |
| title_sort | optimal cytoreduction in advanced ovarian cancer treated with dose dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases |
| topic | neoplasias ováricas quimioterapia terapia neoadyuvante procedimientos quirúrgicos de citorreducción perú |
| url | https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/3599 |
| work_keys_str_mv | AT cindyalcarraz optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT johanamuniz optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT luismas optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT mivaelolivera optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT zaidamorante optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT manuelalvarez optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT raulmantilla optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT jhajairaaraujo optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases AT josephpinto optimalcytoreductioninadvancedovariancancertreatedwithdosedensepaclitaxelandcarboplatinfollowedbyintervalsurgeryattheperuviannationalinstituteofneoplasticdiseases |